/
IMMP
$0.41+$0.02 (+4.38%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$57.5M
147M shares
52-week range
$0.29 – $3.53
4% from low
Exchange
NASDAQ
ADRC
Borrow rate
14.14%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-3.46
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | $139.8K | $7.5M | $3.9M | $170.4K | $3.5M | $3.8M | $5.0M |
| Cost of revenue | $10.0M | $16.6M | $22.5M | $17.2M | $2.1M | $2.1M | $41.5M | $61.4M |
| Gross profit | −$7.4M | −$16.5M | −$15.0M | −$13.4M | −$1.9M | $1.4M | −$37.7M | −$56.4M |
| Gross margin | -279.8% | -11769.3% | -200.2% | -346.2% | -1111.2% | 41.2% | -981.4% | -1117.6% |
| R&D | $10.0M | $16.6M | $20.4M | $17.2M | $31.3M | $28.8M | $41.5M | $61.4M |
| Operating income | −$11.7M | −$20.4M | −$16.0M | −$31.7M | −$33.9M | −$77.7M | −$88.1M | −$126.4M |
| EBITDA | −$10.4M | −$16.5M | −$11.4M | −$17.8M | −$31.9M | −$39.6M | −$44.5M | −$62.9M |
| Net income | −$12.7M | −$16.3M | −$13.5M | −$29.9M | −$32.2M | −$39.9M | −$42.7M | −$61.4M |
| Net margin | -484.6% | -11640.0% | -179.9% | -774.1% | -18906.5% | -1138.0% | -1111.9% | -1218.0% |
| EPS (diluted) | -0.48 | -0.47 | -0.33 | -0.49 | -0.37 | -0.44 | -0.36 | -0.42 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $9M | $-0.27 | $-0.27–$-0.27 | 1 |
| 2027 | $5M | $-0.14 | $-0.14–$-0.14 | 1 |
| 2028 | $2M | $-0.26 | $-0.26–$-0.26 | 1 |
| 2029 | $205M | $-0.33 | $-0.33–$-0.33 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.17
Price
$0.41
Implied downside
-59%
Peer comparison
Immutep Limited American Depositary Shares
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
www.immutep.com- Employees
- 51
- IPO / List date
- Jan 1, 1988
Held by traders on TradeandTell
No one on the platform currently holds IMMP.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IMMP as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2016-12-28 | 1-for-3.333333reverse |
Recent trades on TradeandTell
No one on the platform has traded IMMP yet.
